New take on comparative immunology: Relevance to immunotherapy

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 355-366

  Wang, Ena ^a   Albini, Adriana ^b   Stroncek, David F ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Chronic infection; Comparative immunology; Tumor immunology; Vaccine

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1;

EXPERIMENTAL MODEL; GENETIC POLYMORPHISM; HUMAN; HUMAN GENOME; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; MEDICAL RESEARCH; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNOLOGY; VACCINE PRODUCTION;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; IMMUNOTHERAPY; MODELS, ANIMAL; ORGAN SPECIFICITY; POLYMORPHISM, GENETIC;

EID: 69049108478     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.10     Document Type: Review

References (123)

1. Tettamanti G, Malagoli D, Benelli R et al.: Growth factors and chemokines: a comparative functional approach between invertebrates and vertebrates. Curr. Med Chem. 13(23), 2737-2750 (2006).
2. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25(12), 677-686 (2004). (Pubitemid 39457982)
3. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 371(9614), 771-783 (2008). ■■ Attempts to reconcile the opposing roles that inflammation is believed to play in the development of cancer.
4. Mayer WE, Uinuk-Ool T, Tichy H, Gartland LA, Klein J, Cooper MD: Isolation and characterization of lymphocyte-like cells from a lamprey. Proc. Natl Acad. Sci. USA 99(22), 14350-14355 (2002).
5. Dormer A, Beck G: Evolutionary analysis of human vascular endothelial growth factor, angiopoietin, and tyrosine endothelial kinase involved in angiogenesis and immunity. In Silico Biol. 5(3), 323-339 (2005). (Pubitemid 41136005)
6. Dishaw LJ, Smith SL, Bigger CH: Characterization of a C3-like cDNA in a coral: phylogenetic implications. Immunogenetics 57(7), 535-548 (2005).
7. Kaisho T, Akira S: Pleiotropic function of Toll-like receptors. Microbes Infect. 6(15), 1388-1394 (2004).
8. Jang SI, Hardie LJ, Secombes CJ: Effects of transforming growth factor β 1 on rainbow trout Oncorhynchus mykiss macrophage respiratory burst activity. Dev. Comp. Immunol. 18(4), 315-323 (1994).
9. Strausberg RL, Feingold EA, Grouse LH et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl Acad. Sci. USA 99(26), 16899-16903 (2002).
10. Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731-2738 (2004). ■■ Important documentation of basic genetic difference between mice and humans that needs to be recognized for a correct interpretation of experimental and preclinical data.
11. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI: Structure and functional expression of a human interleukin-8 receptor. Science 253(5025), 1278-1280 (1991). (Pubitemid 21917277)
12. Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253(5025), 1280-1283 (1991).
13. Ottaviani E, Franchini A, Malagoli D, Genedani S: Immunomodulation by recombinant human interleukin-8 and its signal transduction pathways in invertebrate hemocytes. Cell Mol. Life Sci. 57(3), 506-513 (2000).
14. Xie Q, Thompson R, Hardy K et al.: A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J. Transl. Med. 6(1), 77 (2008).
15. Davis MM: A prescription for human immunology. Immunity 29(6), 835-838 (2008).
16. von Herrath MG, Nepom GT: Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med. 202(9), 1159-1162 (2005).
17. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77(7), 527-543 (1999).
18. Quintana-Murci L, Alcais A, Abel L, Casanova JL: Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat. Immunol. 8(11), 1165-1171 (2007).
19. Verani A, Lusso P: Chemokines as natural HIV antagonists. Curr. Mol. Med. 2(8), 691-702 (2002).
20. Marincola FM: Translational medicine: a two way road. J. Transl. Med. 1(1), 1 (2003).
21. Marincola FM: In support of descriptive studies: relevance to translational research. J. Transl. Med. 5, 21 (2007).
22. Wang E, Marincola FM: Bottom up: a modular view of immunology. Immunity 29, 9-11 (2008).
23. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl Cancer Inst. 79(5), 1067-1075 (1987).
24. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321 (1986). (Pubitemid 16002234)
25. Rosenberg SA, Packard BS, Aebersold PM et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680 (1988).
26. Rosenberg SA, Yannelli JR, Yang JC et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159-1166 (1994).
27. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
28. Tang CK, Apostolopoulos V: Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev. Vaccine 7(7), 951-962 (2008).
29. Tang CK, Katsara M, Apostolopoulos V: Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev. Vaccine 7(7), 963-975 (2008).
30. Yajima M, Imadome K, Nakagawa A et al.: A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 198(5), 673-682 (2008).
31. Koo GC, Hasan A, O'Reilly RJ: Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev. Vaccine 8(1), 113-120 (2009).
32. King M, Pearson T, Rossini AA, Shultz LD, Greiner DL: Humanized mice for the study of Type 1 diabetes and β cell function. Ann. NY Acad. Sci. 1150, 46-53 (2008).
33. Chesi M, Robbiani DF, Sebag M et al.: AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13(2), 167-180 (2008). (Pubitemid 351163163)
34. Zuk M: Q&A; Marlene Zuk. Curr. Biol. 18(22), R1041-R1042 (2008).
35. Jin P, Wang E: Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J. Transl. Med. 1, 8 (2003).
36. Klein J: Natural History of the Major Histocompatibility Complex. John Wiley & Sons, NY, USA (1986).
37. Cavalli-Sforza LL: The Human Genome Diversity Project: past, present and future. Nat. Rev. Genet. 6(4), 333-340 (2005).
38. Cavalli-Sforza LL: Human evolution and its relevance for genetic epidemiology. Annu. Rev. Genomics Hum. Genet. 8, 1-15 (2007).
39. Kaufman J, Volk H, Wallny HJ: A 'minimal essential MHC' and an 'unrecognized MHC': two extremes in selection for polymorphism. Immunol. Rev. 143, 63-88 (1995).
40. Liu D, O'Day SJ, Yang D et al.: Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin. Cancer Res. 11(3), 1237-1246 (2005).
41. Ugurel S, Schrama D, Keller G et al.: Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. lmmunother. 57(5), 685-691 (2007).
42. Sneller MC, Straus SE, Jaffe ES et al.: A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J. Clin. Invest. 90(2), 334-341 (1992).
43. Fisher GH, Rosenberg FJ, Straus SE et al.: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81(6), 935-946 (1995).
44. Martin DA, Zheng L, Siegel RM et al.: Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl Acad. Sci. USA 96(8), 4552-4557 (1999).
45. Infante AJ, Britton HA, DeNapoli T et al.: The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J. Pediatr. 133(5), 629-633 (1998). (Pubitemid 28521211)
46. Jackson CE, Fischer RE, Hsu AP et al.: Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am. J. Hum.Genet. 64(4), 1002-1014 (1999).
47. Ryan JG, Kastner DL: Fevers, genes, and innate immunity. Curr. Top. Microbiol. Immunol. 321, 169-184 (2008).
48. Amos CI, Chen WV, Remitters E et al.: Data for genetic analysis workshop (GAW) 15 problem 2, genetic causes of rheumatoid arthritis and associated traits. BMC Proc. 1(Suppl. 1), S3 (2007).
49. van der Pol WL, Kuijper EJ, Koene HR, de Haas M, Sanders EA, van de Winkel JG: Immunology in clinical practice. XI. IgG receptors: the role of polymorphism in autoimmune and infectious diseases. Ned. Tijdschr. Geneeskd. 142(7), 340-345 (1998).
50. Svejgaard A: The immunogenetics of multiple sclerosis. Immunogenetics 60(6), 275-286 (2008).
51. Steinke JW, Rich SS, Borish L: 5. Genetics of allergic disease. J. Allergy Clin. Immunol. 121(Suppl. 2), S384-S387 (2008).
52. Bernig T, Chanock SJ: Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev. Mol. Diagn. 6(3), 319-331 (2006).
53. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet. (Suppl. 33), 228-237 (2003).
54. Teufel A, Krupp M, Weinmann A, Galle PR: Current bioinformatics tools in genomic biomedical research (Review). Int. J. Mol. Med. 17(6), 967-973 (2006).
55. Maniatis N: Linkage disequilibrium maps and disease-association mapping. Methods Mol. Biol. 376, 109-121 (2007).
56. George Priya DC, Sudandiradoss C, Rajasekaran R et al.: Applications of computational algorithm tools to identify functional SNPs. Funct. Integr. Genomics 8(4), 309-316 (2008). ■■ Discusses very well the challenges and potential solutions of studying genotypes to predict phenotypes in the clinical settings.
57. Shastry BS: Genetic diversity and new therapeutic concepts. J. Hum. Genet. 50(7), 321-328 (2005).
58. Alizadeh AA, Eisen MB, Davis RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 467-578 (2000).
59. Perou CM, Sertle T, Eisen MB et al.: Molecular portraits of human breast tumorurs. Nature 406, 747-752 (2000).
60. Bittner M, Meltzer P, Chen Y et al.: Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a countinuous spectrum to distinct biologic entities. Nature 406, 536-840 (2000).
61. Wang E, Miller LD, Ohnmacht GA et al.: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62, 3581-3586 (2002). (Pubitemid 34728828)
62. Wang E, Lichtenfels R, Bukur J et al.: Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res. 64(20), 7279-7287 (2004). (Pubitemid 39372065)
63. Wang E, Voiculescu S, Le Poole IC et al.: Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol. 126(6), 1372-1377 (2006).
64. Sabatino M, Zhao Y, Voiculescu S et al.: Conservation of a core of genetic alterations over a decade of recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 68(1), 222-231 (2008).
65. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 9(4), 138-141 (1993).
66. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396(6712), 643-649 (1998).
67. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA: Can chromosomal instability initiate tumorigenesis? Semin. Cancer Biol. 15(1), 43-49 (2005). (Pubitemid 40018527)
68. Wang E, Panelli MC, Marincola FM: Gene profiling of immune responses against tumors. Curr. Opin. Immunol. 17(4), 423-427 (2005).
69. Wang E, Panelli M, Marincola FM: Autologous tumor rejection in humans: trimming the myths. Immunol. Invest. 35(3-4), 437-458 (2006).
70. Wang E, Selleri S, Sabatino M et al.: Spontaneous and tumor-induced cancer rejection in humans. Exp. Opin. Biol. Ther. 8(3), 337-349 (2008).
71. Cormier JN, Hijazi YM, Abati A et al.: Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75, 517-524 (1998). (Pubitemid 28094095)
72. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA: Loss of functional β 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 88(2), 100-108 (1996). (Pubitemid 2619238)
73. Ohnmacht GA, Wang E, Mocellin S et al.: Short term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167, 1809-1820 (2001).
74. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24(6), 335-342 (2003).
75. Krupovic M, Bamford DH: Virus evolution: how far does the double β-barrel viral lineage extend? Nat. Rev. Microbiol. 6(12), 941-948 (2008).
76. Farci P, Shimoda A, Coiana A et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288(5464), 339-344 (2000). (Pubitemid 30226196)
77. Farci P, Strazzera R, Alter HJ et al.: Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl Acad. Sci. USA 99(5), 3081-3086 (2002).
78. McBurney SP, Ross TM: Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev. Vaccine 7(9), 1405-1417 (2008).
79. Mocellin S, Nitti D: Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med. Res. Rev. 28(3), 413-444 (2008).
80. Mankoff SP, Brander C, Ferrone S, Marincola FM: Lost in translation: obstacles to translational medicine. J. Transl. Med. 2(1), 14 (2004).
81. Littman BH, Di Mario L, Plebani M, Marincola FM: What's next in translational medicine? Clin. Sci. (Lond.) 112(4), 217-227 (2006).
82. Horig H, Marincola E, Marincola FM: Obstacles and opportunities in translational research. Nat. Med. 11(7), 705-708 (2005).
83. Coffey DS: Self-organization, complexity and chaos: the new biology for medicine. Nat. Med. 4(8), 882-885 (1998). ■■ The complexity of biology compared with other theoretical systems and the need for nonlinear mathematical approaches.
84. Cucuianu A: Chaos in cancer? Nat. Med. 4(12), 1342-1343 (1998).
85. Callard R, George AJT, Stark J: Cytokines, chaos and complexity. Cell 11(507), 513 (1999).
86. Dalgleish A: The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. QJM 92, 347-359 (1999).
87. Rew DA: Tumour biology, chaos and non-linear dynamics. Eur. J. Surg. Oncol. 25(1), 86-89 (1999).
88. Butterfield LH, Disis ML, Fox BA et al.: A systematic approach to biomarker discovery; preamble to 'the iSBTc-FDA Taskforce on Immunotherapy Biomarkers'. J. Transl. Med. 6(1), 81 (2008). ■■ Recent manuscript that represents a documentation of a multi-institutional effort to improve the effectiveness of biomarker discovery in the field of tumor immunotherapy.
89. Dyson F: Dream of scientific brotherhood. New York Rev. Books 54(8), 47-52 (2007).
90. vila-Campillo I, Drew K, Lin J, Reiss DJ, Bonneau R: BioNetBuilder: automatic integration of biological networks. Bioinformatics 23(3), 392-393 (2007).
91. Chavali AK, Gianchandani EP, Tung KS, Lawrence MB, Peirce SM, Papin JA: Characterizing emergent properties of immunological systems with multi-cellular rule-based computational modeling. Trends Immunol. 29(12), 589-599 (2008).
92. Benoist C, Germain RN, Mathis D: A plaidoyer for 'systems immunology'. Immunol. Rev. 210, 229-234 (2006).
93. Shapiro M, Duca KA, Lee K et al.: A virtual look at Epstein-Barr virus infection: simulation mechanism. J. Theor. Biol. 252(4), 633-648 (2008).
94. Meier-Schellersheim M, Xu X, Angermann B, Kunkel EJ, Jin T, Germain RN: Key role of local regulation in chemosensing revealed by a new molecular interaction-based modeling method. PLoS Comput. Biol. 2(7), E82 (2006).
95. Germain RN, Bajenoff M, Castellino F et al.: Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol. Rev. 221, 163-181 (2008).
96. Rainer M, Schmidt HJ: Current Topics in Mathematical Cosmology. World Scientific, Potsdam, Germany (2007).
97. Rubin V: Dark matter in the universe. Scientific American Presents (2), 104-110 (1998).
98. Chaussabel D, Quinn C, Shen J et al.: A modular framework for biomarker and knowledge discovery from blood transcriptional profiling studies: application to systemic lupus erythemathosus. Immunity 29(1), 150-164 (2008). ■■ Proposes a bottom-up inductive approach using high-throughput technology for the study of human immune pathologies providing extensive documentation of converging and diverging aspects of disease.
99. Wang E, Worschech A, Marincola FM: The immunologic constant of rejection. Trends Immunol. 29(6), 256-262 (2008). ■■ Suggests a novel hypothesis whereby different diseases characterized by immune-mediated, tissue-specific destruction are the end result of a similar effector mechanism whose signature is characterized by a relatively restricted number of functional pathways.
100. Bialek W, Botstein D: Introductory science and mathematics education for 21st-century biologists. Science 303(5659), 788-790 (2004). (Pubitemid 38174647)
101. Marincola FM: Future of immunotherapy: a call for compartive immunology. Immunotherapy 1(1), 1-3 (2009).
102. Rees J: Complex disease and the new clinical sciences. Science 296(5568), 698-700 (2002).
103. Salk J: Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann. NY Acad. Sci. 164(2), 365-380 (1969). ■■ Classic summary of a workshop held a long time ago and is a great example of forward thinking and of recurrent themes in science.
104. Panelli MC, Wang E, Phan G et al.: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 3(7), RESEARCH0035 (2002).
105. Panelli MC, Stashower M, Slade HB et al.: Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 8(1), R8 (2006). (Pubitemid 351910994)
106. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
107. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
108. Sarwai M, Chua MS, Kambham N et al.: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349(2), 125-138 (2003).
109. He XS, Ji X, Hale MB et al.: Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44(2), 352-359 (2006). (Pubitemid 44214874)
110. Bigger CB, Brasky KM, Lanford RE: DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75(15), 7059-7066 (2001).
111. Ablin RJ, Zeng YX: The excellence in translational medicine award 2006-2007. J. Transl. Med. 5, 40 (2007).
112. Zhang Q, Yu YA, Wang E et al.: Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67(20), 10038-10046 (2007). (Pubitemid 47621255)
113. Pascual V, Farkas L, Banchereau J: Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 18(6), 676-682 (2006).
114. Co JK, Verma S, Gurjav U, Sumibcay L, Nerurkar VR: Interferon-α and -β restrict Polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. J. Infect. Dis. 196(5), 712-718 (2007).
115. Rotrosen D, Matthews JB, Bluestone JA: The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J. Allergy Clin. Immunol. 110(1), 17-23 (2002).
116. Dana R, Nussenblatt R, Gordon L: Advances in immunology: from bench to bedside - a symposium at the 2005 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), Boston, MA, USA. Ocul. Immunol. Inflamm. 14(1), 1-6 (2006).
117. Allantaz F, Chaussabel D, Banchereau J, Pascual V: Microarray-based identification of novel biomarkers in IL-1-mediated diseases. Curr. Opin. Immunol. 19(6), 623-632 (2007).
118. Beasley JR, McCoy PM, Walker TL, Dunn DA: Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev. Technol. 2(2), 141-151 (2004).
119. Aksentijevich I, Galon J, Soares M et al.: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSFIA, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 69(2), 301-314 (2001).
120. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76(2), 287-299 (1994).
121. Germain RN: The ins and outs of antigen processing and presentation. Nature 322, 687-689 (1996).
122. Germain RN, Malissen B: Analysis of the expression and function of class-II major histocompatibility complex-encoded molecules by DNA-mediated gene transfer. Annu. Rev. Immunol. 4, 281-315 (1986).
123. Wang E, Marincola FM: A natural history of melanoma: serial gene expression analysis. Immunol. Today 21(12), 619-623 (2000). (Pubitemid 32044018)